Your Article Summary
See Latest ArticlesCost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis
Current Medical Research and Opinion, 06/23/09
Chiao E et al. - Natalizumab was the most cost-effective therapy as measured by total cost per relapse avoided, not withstanding a higher drug acquisition cost versus other DMTs. Entry of natalizumab to the market is likely to result in a minimal increase in health-plan costs on a PMPM basis. Limitations of the study include the use of a surrogate measure, relapse avoided, as an outcome measure; also, adverse events were not included in the model.
Related Articles
APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis
Multiple Sclerosis, 11/19/09
Relevance Score: 69%
Early Psychiatric Manifestation in a Patient with Primary Progressive Multiple Sclerosis
Archives of Iranian Medicine, 11/12/09
Relevance Score: 69%
Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09
Relevance Score: 69%
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09
Relevance Score: 69%
Early Drug Treatment May Cut Multiple Sclerosis Risk
MedLinePlus, 10/08/09
Relevance Score: 68%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy
Journal of Neuro-Oncology, 12/04/09
Combination therapy of 17(beta)-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain
Molecular Pharmacology, 12/04/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
PLoS Medicine, 12/04/09
Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Imipenem Resistance in Pseudomonas aeruginosa: Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes
Infection Control and Hospital Epidemiology, 12/02/09